ARE STEM CELL MARKER EXPRESSION AND CD133 ANALYSIS RELEVANT TO DIFFERENTIATE COLORECTAL CANCER?

Autor: Fabiola Pabst Bremer, Leticia Elizabeth Augustin Czeczko, Guilherme Gionedis, Ana Maria Waaga-Gasser, Diogo Francesco Castoldi, Thelma Larocca Skare, Camila Kienen Yamakawa, Nicolau Gregori Czeczko, Martin Gasser, Carmen Australia Paredes Marcondes Ribas, Cecilia Vasconcelos
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Male
0301 basic medicine
Oncology
Neoplasias colorretais
Colorectal cancer
neoplasms
Biomarcadores tumorais
RC799-869
Stem cell marker
Metastasis
fluids and secretions
0302 clinical medicine
Receptores proteína tirosina quinases
Neoplasm Metastasis
Univariate analysis
Tissue microarray
Proteínas proto-oncogênicas
General Medicine
Diseases of the digestive system. Gastroenterology
Prognosis
030220 oncology & carcinogenesis
embryonic structures
cardiovascular system
Neoplastic Stem Cells
Female
Original Article
Adenoma
medicine.medical_specialty
RD1-811
Colorectal neoplasms
03 medical and health sciences
Cancer stem cell
Antigens
CD
Internal medicine
Antígeno ac133
medicine
Humans
Glycoproteins
AC133 antigen
business.industry
Proto-oncogene proteins c-MYC
Receptor protein tyrosine-kinase
medicine.disease
digestive system diseases
carbohydrates (lipids)
C-myc
030104 developmental biology
Dysplasia
Biomarkers
tumor
Surgery
business
Peptides
Zdroj: ABCD: Arquivos Brasileiros de Cirurgia Digestiva, Vol 34, Iss 2 (2021)
Arquivos Brasileiros de Cirurgia Digestiva : ABCD
ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo) v.33 n.4 2020
ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo)
Colégio Brasileiro de Cirurgia Digestiva (CBCD)
instacron:CBCD
ABCD: Arquivos Brasileiros de Cirurgia Digestiva, Vol 33, Iss 4 (2021)
ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo) v.34 n.2 2021
ISSN: 0102-6720
Popis: A) CD133+ cytoplasmic B) AXL+ combined C) c-MYC+ nuclear
Background: CD133 and AXL have been described as cancer stem cell markers, and c-MYC as a key regulatory cellular mechanism in colorectal cancer (CRC). Aim: Evaluate the prognostic role of the biomarkers CD133, AXL and c-MYC and their association with clinicopathologic characteristics in colorectal adenocarcinomas and adenomas. Methods: A total of 156 patients with UICC stage I-IV adenocarcinomas (n=122) and adenomas (n=34) were analyzed. Tissue microarrays (TMA) from primary tumors and polyps for CD133, c-MYC and AXL expression were performed and analyzed for their significance with clinicopathologic characteristics. Results: Poorly differentiated adenocarcinomas and disease progression were independent risk factors for poor overall survival. The median overall survival time was 30 months. Positive CD133 expression (35.9% of all cases), particularly of right-sided CRCs (44.8% of the CD133+ cases), was negatively correlated with death in the univariate analysis, which did not reach significance in the multivariate analysis. c-MYC (15.4% of all cases) was predominantly expressed in advanced-stage patients with distant (non-pulmonary/non-hepatic) metastasis. AXL expression was found only occasionally, and predominantly dominated in adenomas, with less penetrance in high-grade dysplasia. Conclusions: CD133 expression was not associated with inferior overall survival in CRC. While AXL showed inconclusive results, c-MYC expression in primary CRCs was associated with distant metastasis.
Databáze: OpenAIRE
Externí odkaz: